These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17982714)

  • 1. Usefulness and problems of the urinary tract infection criteria for evaluating drug efficacy for complicated urinary tract infections.
    Arakawa S; Tanaka K; Miura T; Shigemura K; Takenaka A; Matsui T; Kamidono S; Nakano Y; Fujisawa M
    J Infect Chemother; 2007 Oct; 13(5):279-84. PubMed ID: 17982714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical study of complicated urinary tract infection using 'The UTI Criteria (Draft Fourth Edition)': measurement methods for pyuria.
    Arakawa S; Nakano Y; Miura T; Shigemura K; Tanaka K; Fujisawa M
    Int J Urol; 2006 Dec; 13(12):1484-7. PubMed ID: 17118022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Multicentric study for evaluation of levofloxacin in the treatment of complicated urinary tract infections].
    Trinchieri A; Marchetti F
    Arch Ital Urol Androl; 2003 Mar; 75(1):49-52. PubMed ID: 12741347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of ofloxacin against complicated urinary tract infections].
    Nishio S; Yoshihara H
    Hinyokika Kiyo; 1987 Sep; 33(9):1503-7. PubMed ID: 3481217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Reevaluation of clinical efficacy of piperacillin against complicated urinary tract infections].
    Ueno M; Ikeuchi T; Kai Y
    Hinyokika Kiyo; 1988 Sep; 34(9):1675-8. PubMed ID: 3213800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of high-dose levofloxacin therapy remain bound to the levofloxacin minimum inhibitory concentration in complicated urinary tract infections.
    Armstrong ES; Mikulca JA; Cloutier DJ; Bliss CA; Steenbergen JN
    BMC Infect Dis; 2016 Nov; 16(1):710. PubMed ID: 27887579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A clinical evaluation of CS-807 in patients with urinary tract infections].
    Nakajima K; Oshinoya Y; Uchibayashi T; Ohkawa M; Hisazumi H
    Hinyokika Kiyo; 1988 Aug; 34(8):1515-8. PubMed ID: 3195413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term treatment and clinical evaluation of enoxacin in complicated urinary tract infections].
    Washida H; Sakagami H; Iwase Y; Sasaki S
    Hinyokika Kiyo; 1987 Sep; 33(9):1508-12. PubMed ID: 3481218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study of ofloxacin (OFLX) on urinary tract infections].
    Miyata M; Inagaki N; Inada F; Yachiku S; Okamura K; Osanai H; Mizunaga M; Morikawa M
    Hinyokika Kiyo; 1987 Aug; 33(8):1303-11. PubMed ID: 3480688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).
    Wagenlehner FM; Umeh O; Steenbergen J; Yuan G; Darouiche RO
    Lancet; 2015 May; 385(9981):1949-56. PubMed ID: 25931244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical experience with ceftibuten in complicated urinary tract infections].
    Mizutani S; Nishimura K; Yoshimura K; Miyoshi S; Iwao N; Higashimoto J; Shiota K
    Jpn J Antibiot; 1990 May; 43(5):779-89. PubMed ID: 2391749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mecillinam resistance and outcome of pivmecillinam treatment in uncomplicated lower urinary tract infection in women.
    Monsen TJ; Holm SE; Ferry BM; Ferry SA
    APMIS; 2014 Apr; 122(4):317-23. PubMed ID: 24738161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Criteria for evaluation of clinical efficacy of antimicrobial agents on urinary tract infection. UTI Subcommittee of the Clinical Evaluation Committee, Japan Society of Chemotherapy.
    Jpn J Antibiot; 2000 Jun; 53(6):453-77. PubMed ID: 10955240
    [No Abstract]   [Full Text] [Related]  

  • 14. [Role of levofloxacin in the treatment of urinary tract infections].
    Trinchiere A
    Arch Ital Urol Androl; 2001 Jun; 73(2):105-13. PubMed ID: 11758533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical trials of flomoxef in complicated urinary tract infections].
    Ohta N; Sudoko H; Fukuta K; Nakano M; Ushiyama T; Tajima A; Aso Y; Masuda H; Suzuki A; Suzuki K
    Jpn J Antibiot; 1987 Oct; 40(10):1835-44. PubMed ID: 3444025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical experience with T-2588 in complicated urinary tract infections].
    Fukatsu H; Nonomura H; Ohshita H; Miyagawa Y; Hatano Y; Waki M; Takamura T; Hiraiwa S; Yamada Y; Muramatsu T
    Hinyokika Kiyo; 1986 Jul; 32(7):1061-8. PubMed ID: 3776768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: a randomized controlled trial.
    Bjerrum L; Gahrn-Hansen B; Grinsted P
    Scand J Prim Health Care; 2009; 27(1):6-11. PubMed ID: 18991182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of complicated urinary tract infection and acute pyelonephritis by short-course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500 mg/day): prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial.
    Ren H; Li X; Ni ZH; Niu JY; Cao B; Xu J; Cheng H; Tu XW; Ren AM; Hu Y; Xing CY; Liu YH; Li YF; Cen J; Zhou R; Xu XD; Qiu XH; Chen N
    Int Urol Nephrol; 2017 Mar; 49(3):499-507. PubMed ID: 28108978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of intravenous doripenem for the treatment of complicated urinary tract infections and pyelonephritis.
    Redman R; Damiao R; Kotey P; Kaniga K; Davies T; Naber KG
    J Chemother; 2010 Dec; 22(6):384-91. PubMed ID: 21303745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A study on the treatment duration of an antibacterial agent in complicated urinary tract infections. Utility and recurrence after 14-day treatment by fleroxacin].
    Arakawa S; Takagi S; Matsumoto O; Kamidono S; Sengoku A; Hazama M; Yamazaki H; Hamami G; Okamoto Y; Tanaka H
    Jpn J Antibiot; 1991 Jul; 44(7):718-31. PubMed ID: 1909383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.